Schizophrenia

British Medical Journal

Volumn 335, Issue 7610, 2007, Pages 91-95

  Picchioni, Marco M ^a   Murray, Robin M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

AGRANULOCYTOSIS; AKATHISIA; ASPIRATION PNEUMONIA; BLURRED VISION; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; COGNITION; COGNITIVE THERAPY; CONSTIPATION; DELUSION; DIABETES MELLITUS; DROWSINESS; DYSPEPSIA; DYSTONIA; ENVIRONMENTAL FACTOR; EXTRAPYRAMIDAL SYNDROME; FAMILY THERAPY; FEVER; GLUCOSE INTOLERANCE; HALLUCINATION; HEREDITY; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; HYPERTENSION; HYPOTENSION; INCIDENCE; INSOMNIA; MEMORY DISORDER; MYOCARDITIS; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; NOCTURNAL ENURESIS; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SEIZURE THRESHOLD; SEX RATIO; SEXUAL DYSFUNCTION; SIDE EFFECT; SYSTEMATIC REVIEW; TACHYCARDIA; TARDIVE DYSKINESIA; THOUGHT DISORDER; THROMBOEMBOLISM; URINE RETENTION; WEIGHT GAIN; XEROSTOMIA; EARLY DIAGNOSIS; HOSPITALIZATION; LONG TERM CARE; METHODOLOGY; PRIMARY HEALTH CARE; PROGNOSIS; PSYCHOTHERAPY;

ANTIPSYCHOTIC AGENTS; EARLY DIAGNOSIS; HOSPITALIZATION; HUMANS; LONG-TERM CARE; PRIMARY HEALTH CARE; PROGNOSIS; PSYCHOTHERAPY; SCHIZOPHRENIA;

EID: 34447634886     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39227.616447.BE     Document Type: Review

References (24)

1. Hanssen M, Bak M, Bijl R, Vollebergh W, van Os J. The incidence and outcome of subclinical psychotic experiences in the general population. Br J Clin Psychol 2005;44:181-91.
2. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PloS Med 2005;2:413-33.
3. McGrath JJ, Saha S, Welham J, El-Saadi O, MacCauley C, Chant DC. A systematic review of the incidence of schizophrenia: the distribution of rate items and the influence of methodology, urbanicity, sex and migrant status. Schizophr Res 2004;67:65-6.
4. Jablensky A. Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci 2000;250:274-85.
5. Pedersen CB, Mortensen PB. Evidence of a dose-response relationship between urbanicity during upbringing and schizophrenia risk. Arch Gen Psychiatry 2001;58:1039-46.
6. McGrath JJ. Variations in the incidence of schizophrenia: data versus dogma. Schizophr Bull 2006;32:195-7.
7. Boydell J, van Os J, McKenzie K, Allardyce J, Goel R, McCreadie RG, et al. Incidence of schizophrenia in ethnic minorities in London: ecological study into interactions with environment. BMJ 2001;323:1336-8.
8. Kendler KS, McGuire M, Gruenberg AM, Ohare A, Spellman M, Walsh D. The Roscommon family study. 1. Methods, diagnosis of probands, and risk of schizophrenia in relatives. Arch Gen Psychiatry 1993;50:527-40.
9. Cardno AG, Marshall EJ, Coid B, Macdonald AM, Ribchester TR, Davies NJ, et al. Heritability estimates for psychotic disorders. Arch Gen Psychiatry 1999;56:162-8.
10. Boydell J, van Os J, McKenzie K, Murray RM. The association of inequality with the incidence of schizophrenia - an ecological study. Social Psychiatry Psychiatr Epidemiol 2004;39:597-9.
11. Broome MR, Wooley JB, Tabraham P, Johns LC, Bramon E, Murray GK, et al. What causes the onset of psychosis? Schizophr Res 2005;79:23-34.
12. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002;325:1212-3.
13. Henquet C, Murray R, Linszen D, van Os J. The environment and schizophrenia: the role of cannabis use. Schizophr Bull 2005;31:608-12.
14. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005;57:1117-27.
15. National Institute for Health and Clinical Excellence. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. London: NICE, 2002.
16. Perkins DO, Hongbin G, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005;162:1785-804.
17. Marshall M, Rathbone J. Early intervention for psychosis. Cochrane Database Syst Rev 2006;(4):CD004718.
18. Adams CE. Schizophrenia. Full national clinical guideline on core interventions in primary and secondary care. London: Gaskell and the British Psychological Society, 2003.
19. Taylor D, Kerwin R, Paton C. The Maudsley 2005-2006 prescribing guidelines, 8th ed. London: Taylor and Francis, 2005.
20. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999;156:990-9.
21. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomised controlled trial of the effect on quality of life of second-vs first-generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry 2006;63:1079-87.
22. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23.
23. Jones C, Cormac I, Silveira da Mota Neto JI, Campbell C. Cognitive behavioural therapy for schizophrenia. Cochrane Database Syst Rev 2004;(4):CD000524.
24. Robinson D, Woerner MG, Alvir JMJ, Bilder R, Goldman R, Geisler S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241-7.